TCOP联合平阳霉素治疗中高度非霍奇金淋巴瘤的临床研究  

Clinical Study on Treatment of Intermediate or High-grade Non-Hodgkin Lymphoma with a Combination of TCOP and Pingyangmycin

作　　者：陆紫敏[1] 朱海平[2] 修冰[1] 付建非[1] 薄兰君[1] 顾凤英[1] 

机构地区：[1]同济大学附属同济医院血液科,上海市200065 [2]上海市闸北区中心医院内科

出　　处：《中国肿瘤临床》2004年第11期617-619,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨TCOP-P(TCOP联合平阳霉素)方案治疗中、高危非霍奇金淋巴瘤的疗效。方法:将66例患者随机分为两组。TCOP-P方案35例(A组)和CHOP方案31例(B组)。每21天重复疗程,全部患者接受6～8个周期治疗。结果:A组完全缓解(CR)、总有效率、3年生存率分别为57.1%、88.5%和73.5%,均明显高于B组(P<0.05);3年复发率和心肌损害率均明显低于B组。结论:TCOP-P方案治疗中高危非霍奇金淋巴瘤疗效明显优于CHOP方案,可以提高完全缓解率、延长生存时间、减少复发率。Objective: To investigate a more effective method for treatment intermediate or high grade non-Hodgkin Lymphoma (NHL). Methods: According to the diagnostic criteria of International Working Formulation (IWF), sixty-six cases were divided into two groups randomly, with thirty-one cases for the CHOP group and thirty-five cases for the COP-P group. The CHOP and TCOP were given with Pingyangmycin (TCOP-P) one time three weeks for six to eight courses, respectively. Results: The data showed that the total complete remission (CR) rate, partials remission (PR) rate and three-year survival rate of TCOP-P group were significantly greater than those of CHOP group; three-year recurrence rate and myocardial damage of TCOP-P group were lower than those of CHOP group. Conclusion: TCOP-P is an effective method for treatment intermediate or high grade NHL.TCOP-P can improve the rate of CR and prolong the survival time with reducing recurrence rate.

关 键 词：淋巴瘤 化疗 疗效 

分 类 号：R733.1[医药卫生—肿瘤]